PHVS
Pharvaris·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PHVS
Pharvaris N.V.
A clinical-stage company that develops novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks
Emmy Noetherweg 2, 2333 BK Leiden, The Netherlands
--
Pharvaris N.V. was incorporated in the Netherlands on September 30, 2015. They are a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for unmet needs for rare diseases, with an initial focus on angioedema and other bradykinin-mediated diseases. Their first molecule, PHA 121, is a novel small molecule bradykinin B2 receptor antagonist for the treatment of hereditary angioedema, or HAE.
Company Financials
EPS
PHVS has released its 2025 Q2 earnings. EPS was reported at -0.83, versus the expected -0.893893, beating expectations. The chart below visualizes how PHVS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
